Janus Henderson Group PLC I Teos Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.95 - $14.6 $5.48 Million - $7.3 Million	500,324 New	500,324 $5.48 Million
Q1 2023 May 15, 2023	BUY	$13.02 - $22.62 $359,169 - $623,995	27,586 Added 61.77%	72,246 $983,000
Q4 2022 Feb 14, 2023	SELL	$17.77 - $21.6 $62,088 - $75,470	-3,494 Reduced 7.26%	44,660 $872,000
Q3 2022 Nov 14, 2022	SELL	$18.6 - $27.25 $5,654 - $8,284	-304 Reduced 0.63%	48,154 $918,000
Q2 2022 Aug 15, 2022	BUY	$16.57 - $35.1 $802,949 - $1.7 Million	48,458 New	48,458 $998,000
Q3 2021 Nov 16, 2021	SELL	$23.91 - $29.58 $25.3 Million - $31.3 Million	-1,056,545 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$17.9 - $36.1 $2.09 Million - $4.21 Million	-116,663 Reduced 9.94%	1,056,545 $27.1 Million
Q1 2021 May 17, 2021	SELL	$30.86 - $44.2 $25.1 Million - $36 Million	-814,922 Reduced 40.99%	1,173,208 $40.1 Million
Q4 2020 Feb 16, 2021	BUY	$21.59 - $33.95 $21.3 Million - $33.6 Million	988,298 Added 98.85%	1,988,130 $64.7 Million
Q3 2020 Nov 16, 2020	BUY	$17.57 - $32.92 $17.6 Million - $32.9 Million	999,832 New	999,832 $24.7 Million

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.